Reimbursement, Sales Critical For IPOs As Markets Reopen To Device Firms
This article was originally published in The Gray Sheet
Executive Summary
"Reimbursement clarity" is essential for device firms in gaining investor confidence in the public equity market, Jeffrey Hoffman, health technology investment banker with U.S. Bancorp Piper Jaffray, emphasized at the recent Frost & Sullivan 5th Annual Medical Devices and Diagnostics Industry Conference in San Francisco.
You may also be interested in...
Conceptus Phase III STOP Trial Designed To Show Clinical And Cost Benefit
Conceptus intends to secure third-party reimbursement by examining cost-effectiveness endpoints as a part of Phase III pivotal studies of the firm's STOP non-surgical permanent female contraceptive device.
Conceptus Phase III STOP Trial Designed To Show Clinical And Cost Benefit
Conceptus intends to secure third-party reimbursement by examining cost-effectiveness endpoints as a part of Phase III pivotal studies of the firm's STOP non-surgical permanent female contraceptive device.
HCFA Officials Seek To Protect Local Coverage Review Flexibility
The ongoing reform of the Health Care Financing Administration's coverage review process should preserve the ability of Medicare carriers to develop local policy, according to HCFA Administrator Nancy-Ann DeParle.